Practice Committee of the American Society for Reproductive Medicine (2021). Fertility evaluation of infertile women: a committee opinion. Fertility and sterility, 116(5), 1255-1265. https://doi.org/10.1016/j.fertnstert.2021.08.038
Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertility and sterility. 2021;116(5):1255-1265. doi:10.1016/j.fertnstert.2021.08.038
Practice Committee of the American Society for Reproductive Medicine. "Fertility evaluation of infertile women: a committee opinion." Fertility and sterility, vol. 116, no. 5, 2021, pp. 1255-1265.
For EndNote, Zotero or Mendeley:
Open access
Free to read
No reuse license
Free to read at the publisher (reported by Unpaywall and OpenAlex, not verified by RRM Academy)
RRM Academy Synopsis
ASRM advises least invasive tests first in evaluating infertile women
A 2021 committee opinion from the American Society for Reproductive Medicine (ASRM) says the least invasive tests for the most common causes should come first in infertile women. It notes a thorough period history may be enough to show ovulation in regular cycles. Both partners should be checked at the same time when a male partner gives sperm, it adds.
Key Findings
Absent warning signs, the committee says evaluation should begin after 12 months of trying under age 35, after 6 months from age 35, and possibly sooner over age 40.
The committee reports that ovulation problems are found in approximately 15% of infertile couples and make up as much as 40% of female infertility.
The committee calls female age the most important predictor of pregnancy chances and ovarian reserve a poor predictor of fertility, and advises against ovarian reserve screening in women without infertility.
The committee reports uterine abnormalities in 16.2% of women presenting for infertility evaluation, most often polyps (13%) and submucous fibroids (2.8%), rising to 39.6% in women with abnormal uterine bleeding.
Without other clinical indications, the committee does not recommend laparoscopy, advanced sperm function testing, postcoital testing, thrombophilia or immunologic testing, karyotype, endometrial biopsy, or serum prolactin as routine tests.
Interpretation
The source is a committee opinion, a guidance paper that the ASRM Practice Committee drafted and the society's board approved. The committee reviews the tests now used for infertile women, and the paper replaces its 2015 edition. Its figures come from earlier published studies. The paper addresses women, and a separate paper describes how the male partner is evaluated. The committee says the pace and extent of testing should fit the couple's wishes, the woman's age, how long infertility has lasted, and her history and exam. The committee also states that the paper does not dictate a single course of treatment.
RRM Context
Restorative reproductive medicine (RRM) shares the committee's aim to find the cause in both partners. RRM reads unexplained infertility as a diagnosis not yet made. The committee says only laparoscopy, a keyhole surgery, can make a specific diagnosis of pelvic causes such as endometriosis. It adds that such causes should be weighed when no other cause is found. The committee finds temperature charts often unreliable. In the Creighton Model FertilityCare System, women chart cervical mucus and bleeding each day by a standard method.
Our editorial summary of this paper, not the article's abstract.
Abstract
Diagnostic evaluation for infertility in women should be conducted in a systematic, expeditious, and cost-effective manner to identify all the relevant factors with an initial emphasis on the least invasive methods for detecting the most common causes of infertility. The purpose of this committee opinion is to provide a critical review of the current methods and procedures for the evaluation of in fertile women, and it replaces the document of the same name, last published in 2015 (Fertil Steril 2015;103:e44-50). This guidance is intended for any provider evaluating women for infertility.
Infertility › Evaluation › Diagnostic Workup · Diagnostics › Hormone Testing › Serum Panels · Clinical Guidelines and Standards › Guidelines by Clinical Area › Fertility and Infertility Guidelines
Alan Penzias, Ricardo Azziz, Kristin Bendikson, Marcelle Cedars, Tommaso Falcone, Karl Hansen, Micah Hill, Sangita Jindal, Suleena Kalra, Jennifer Mersereau, Catherine Racowsky, Richard Reindollar, Chevis N Shannon, Anne Steiner, Dale Stovall, Cigdem Tanrikut, Hugh Taylor, Belinda Yauger
A Penzias, R Azziz, K Bendikson, M Cedars, T Falcone, K Hansen, M Hill, S Jindal, S Kalra, Jen Mersereau, Jenny Mersereau, J Mersereau, Cathy Racowsky, Kate Racowsky, C Racowsky, Rick Reindollar, Dick Reindollar, Rich Reindollar, R Reindollar, C Shannon, A Steiner, D Stovall, C Tanrikut, H Taylor, B Yauger
PMID 34607703 34607703 DOI 10.1016/j.fertnstert.2021.08.038 10.1016/j.fertnstert.2021.08.038 Practice Committee of the American Society for Reproductive Medicine et al. 2021, Practice Committee of the American Society for Reproductive Medicine 2021